Proton therapy developer Ion Beam Applications (IBA) has sold its RadioMed unit to IZI Medical Products for an estimated price of 12.6 million euros to 16.6 million euros.
RadioMed, which IBA acquired in 2003, makes Visicoil, an implantable fiducial marker for soft-tissue tumor localization designed to enhance the accuracy of radiation therapy planning and delivery. IZI develops, manufactures, and provides medical consumable devices for interventional radiology and oncology, radiation therapy, neuro-spine, and image-guided surgery procedures.
IBA will retain ownership of the rest of its dosimetry products and business.
